Hexal has announced the appointment of Lamminger to their board of directors
Susanne Lamminger, a seasoned professional with a rich background in health policy and the pharmaceutical industry, has made a significant career move. After serving as the Head of Public Affairs at Sandoz since February 2024, she has been appointed to the Management Board of Hexal, effective immediately.
Prior to her tenure at Sandoz, Lamminger held a position at Bayer, where she worked as the Director of Health Policy. Her extensive experience in the pharmaceutical sector, coupled with her political background, is expected to contribute significantly to her success at Hexal.
Lamminger's political experience spans across multiple institutions. She has worked in the Bundestag and the European Parliament, and her time in the European Parliament is particularly noteworthy. Her expertise in health policy, developed through her work in both the public and private sectors, is a valuable asset in the pharmaceutical distribution industry.
Lamminger's appointment at Hexal marks a shift from the pharmaceutical manufacturing sector to distribution. This move underscores her versatility and adaptability in navigating the complex landscape of the pharmaceutical industry.
However, the details of Lamminger's career progression within Hexal, Bayer, and her legislative experience remain largely undisclosed. Further sources or direct biographical information are necessary to provide a comprehensive profile of her career at these organisations.
Lamminger's departure from Sandoz creates a vacancy in the Head of Corporate Affairs position at Sandoz Germany. Her departure marks the end of a tenure that began in February 2024, a period during which she played a crucial role in shaping the company's public affairs strategy.
As Lamminger embarks on her new journey with Hexal, her contributions to the pharmaceutical industry continue to resonate. Her extensive experience and expertise are poised to make a lasting impact on the Management Board of Hexal.
- Susanne Lamminger's expertise in health policy, gained from both the public and private sectors, will be beneficial in the health-and-wellness sector as well, given her appointment at Hexal.
- The shift in Lamminger's career from the pharmaceutical manufacturing sector to distribution highlights her potential in finance, specifically in business development and financial decision-making at Hexal.
- With her professional background in public affairs, science, and careers in the pharmaceutical industry, Susanne Lamminger's skillset is well-suited for driving strategic initiatives in the broader health and science sectors.
